Clinical trial
Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
NCT00135356 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00135356 |
|---|---|
| Title | Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome |
| Official title | A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study) |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV-Associated Lipodystrophy Syndrome |
| Intervention type | Drug |
| Interventions | Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) |
| Enrollment | 219 |
| Start date | Jul 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Aug 26, 2005 |
| Last update posted | May 7, 2010 |
| Countries | Canada, France, Germany, Italy, Mexico, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: